202 related articles for article (PubMed ID: 28165227)
21. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.
Jiao L; Liu X
Science; 2015 Oct; 350(6258):aac4383. PubMed ID: 26472914
[TBL] [Abstract][Full Text] [Related]
22. Nucleation and Propagation of Heterochromatin by the Histone Methyltransferase PRC2: Geometric Constraints and Impact of the Regulatory Subunit JARID2.
Ge EJ; Jani KS; Diehl KL; Müller MM; Muir TW
J Am Chem Soc; 2019 Sep; 141(38):15029-15039. PubMed ID: 31479253
[TBL] [Abstract][Full Text] [Related]
23. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
24. Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.
Bao Q; Kumar A; Wu D; Zhou J
Drug Discov Today; 2024 Jun; 29(6):103986. PubMed ID: 38642703
[TBL] [Abstract][Full Text] [Related]
25. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
26. SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.
Curtin ML; Pliushchev MA; Li HQ; Torrent M; Dietrich JD; Jakob CG; Zhu H; Zhao H; Wang Y; Ji Z; Clark RF; Sarris KA; Selvaraju S; Shaw B; Algire MA; He Y; Richardson PL; Sweis RF; Sun C; Chiang GG; Michaelides MR
Bioorg Med Chem Lett; 2017 Apr; 27(7):1576-1583. PubMed ID: 28254486
[TBL] [Abstract][Full Text] [Related]
27. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
[TBL] [Abstract][Full Text] [Related]
28. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
Catalano R; Rocca R; Juli G; Costa G; Maruca A; Artese A; Caracciolo D; Tagliaferri P; Alcaro S; Tassone P; Amodio N
Eur J Med Chem; 2019 Dec; 183():111715. PubMed ID: 31550663
[TBL] [Abstract][Full Text] [Related]
29. Structural analysis of an active fungal PRC2.
Jiao L; Liu X
Nucleus; 2016 May; 7(3):284-91. PubMed ID: 27187637
[TBL] [Abstract][Full Text] [Related]
30. JARID2 and AEBP2 regulate PRC2 in the presence of H2AK119ub1 and other histone modifications.
Kasinath V; Beck C; Sauer P; Poepsel S; Kosmatka J; Faini M; Toso D; Aebersold R; Nogales E
Science; 2021 Jan; 371(6527):. PubMed ID: 33479123
[TBL] [Abstract][Full Text] [Related]
31. EED orchestration of heart maturation through interaction with HDACs is H3K27me3-independent.
Ai S; Peng Y; Li C; Gu F; Yu X; Yue Y; Ma Q; Chen J; Lin Z; Zhou P; Xie H; Prendiville TW; Zheng W; Liu Y; Orkin SH; Wang DZ; Yu J; Pu WT; He A
Elife; 2017 Apr; 6():. PubMed ID: 28394251
[TBL] [Abstract][Full Text] [Related]
32. The Complexity of PRC2 Subcomplexes.
van Mierlo G; Veenstra GJC; Vermeulen M; Marks H
Trends Cell Biol; 2019 Aug; 29(8):660-671. PubMed ID: 31178244
[TBL] [Abstract][Full Text] [Related]
33. A novel form of JARID2 is required for differentiation in lineage-committed cells.
Al-Raawi D; Jones R; Wijesinghe S; Halsall J; Petric M; Roberts S; Hotchin NA; Kanhere A
EMBO J; 2019 Feb; 38(3):. PubMed ID: 30573669
[TBL] [Abstract][Full Text] [Related]
34. Identification of SET/EED dual binders as innovative PRC2 inhibitors.
Catalano R; Maruca A; Rocca R; Tassone P; Panzarella G; Costa G; Ortuso F; Alcaro S
Future Med Chem; 2022 May; 14(9):609-621. PubMed ID: 35348013
[No Abstract] [Full Text] [Related]
35. Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
O' Donovan DH; Gregson C; Packer MJ; Greenwood R; Pike KG; Kawatkar S; Bloecher A; Robinson J; Read J; Code E; Hsu JH; Shen M; Woods H; Barton P; Fillery S; Williamson B; Rawlins PB; Bagal SK
Bioorg Med Chem Lett; 2021 May; 39():127904. PubMed ID: 33684441
[TBL] [Abstract][Full Text] [Related]
36. Structure of the PRC2 complex and application to drug discovery.
Shi Y; Wang XX; Zhuang YW; Jiang Y; Melcher K; Xu HE
Acta Pharmacol Sin; 2017 Jul; 38(7):963-976. PubMed ID: 28414199
[TBL] [Abstract][Full Text] [Related]
37. An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response.
Dong H; Liu S; Zhang X; Chen S; Kang L; Chen Y; Ma S; Fu X; Liu Y; Zhang H; Zou B
Cancer Res; 2019 Nov; 79(21):5587-5596. PubMed ID: 31395608
[TBL] [Abstract][Full Text] [Related]
38. Polycomb recruitment at the Class II transactivator gene.
Boyd NH; Morgan JE; Greer SF
Mol Immunol; 2015 Oct; 67(2 Pt B):482-91. PubMed ID: 26283540
[TBL] [Abstract][Full Text] [Related]
39. Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin.
Lee CH; Yu JR; Kumar S; Jin Y; LeRoy G; Bhanu N; Kaneko S; Garcia BA; Hamilton AD; Reinberg D
Mol Cell; 2018 May; 70(3):422-434.e6. PubMed ID: 29681499
[TBL] [Abstract][Full Text] [Related]
40. Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators.
Danishuddin ; Subbarao N; Faheem M; Khan SN
Drug Discov Today; 2019 Jan; 24(1):179-188. PubMed ID: 30031878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
